Exagen Inc. (XGN) got here out with a quarterly lack of $0.19 per share versus the Zacks Consensus Estimate of a lack of $0.13. This compares to a lack of $0.28 per share a yr in the past. These figures are adjusted for non-recurring gadgets.
This quarterly report represents an earnings shock of -46.15%. 1 / 4 in the past, it was anticipated that this firm would submit a lack of $0.18 per share when it truly produced a lack of $0.18, delivering no shock.
During the last 4 quarters, the corporate has surpassed consensus EPS estimates simply as soon as.
Exagen, which belongs to the Zacks Medical – Merchandise trade, posted revenues of $17.24 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.55%. This compares to year-ago revenues of $12.51 million. The corporate has topped consensus income estimates 4 instances during the last 4 quarters.
The sustainability of the inventory’s rapid value motion based mostly on the recently-released numbers and future earnings expectations will largely rely on administration’s commentary on the earnings name.
Exagen shares have added about 188.5% because the starting of the yr versus the S&P 500’s acquire of 16.5%.
What’s Subsequent for Exagen?
Whereas Exagen has outperformed the market to date this yr, the query that involves buyers’ minds is: what’s subsequent for the inventory?
There aren’t any simple solutions to this key query, however one dependable measure that may assist buyers tackle that is the corporate’s earnings outlook. Not solely does this embrace present consensus earnings expectations for the approaching quarter(s), but additionally how these expectations have modified these days.
Empirical analysis reveals a robust correlation between near-term inventory actions and tendencies in earnings estimate revisions. Buyers can observe such revisions by themselves or depend on a tried-and-tested ranking instrument just like the Zacks Rank, which has a formidable observe file of harnessing the facility of earnings estimate revisions.
Forward of this earnings launch, the estimate revisions pattern for Exagen was combined. Whereas the magnitude and path of estimate revisions might change following the corporate’s just-released earnings report, the present standing interprets right into a Zacks Rank #3 (Maintain) for the inventory. So, the shares are anticipated to carry out according to the market within the close to future. You possibly can see the entire listing of in the present day’s Zacks #1 Rank (Robust Purchase) shares right here.
Will probably be fascinating to see how estimates for the approaching quarters and the present fiscal yr change within the days forward. The present consensus EPS estimate is -$0.09 on $18.03 million in revenues for the approaching quarter and -$0.66 on $67.65 million in revenues for the present fiscal yr.
Buyers must be aware of the truth that the outlook for the trade can have a fabric affect on the efficiency of the inventory as properly. When it comes to the Zacks Business Rank, Medical – Merchandise is at present within the backside 41% of the 250 plus Zacks industries. Our analysis reveals that the highest 50% of the Zacks-ranked industries outperform the underside 50% by an element of greater than 2 to 1.
FitLife Manufacturers Inc. (FTLF), one other inventory in the identical trade, has but to report outcomes for the quarter ended September 2025.
This firm is anticipated to submit quarterly earnings of $0.25 per share in its upcoming report, which represents a year-over-year change of +8.7%. The consensus EPS estimate for the quarter has remained unchanged during the last 30 days.
FitLife Manufacturers Inc.’s revenues are anticipated to be $23.75 million, up 48.6% from the year-ago quarter.
Exagen Inc. (XGN) : Free Inventory Evaluation Report
FitLife Manufacturers Inc. (FTLF) : Free Inventory Evaluation Report
This text initially revealed on Zacks Funding Analysis (zacks.com).
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially replicate these of Nasdaq, Inc.
